retatrutide clinical trial status safety trials A new clinical from Eli Lilly and Company suggests its experimental Retatrutide: A Promising Option for
Description
References Huang Y, Li Y, Pan H, Han L
Domain 8: Method of measurement of outcome
Ready to lose weight with the tailored treatment plan today under a physician's guidance
IEEE J Biomed Health Inform
It established two cohorts: 244,063 patients in the GLP-1 RA treatment group (Victoza, Saxenda, Ozempic, Wegovy) and 11,439,560 patients in the non-GLP-1 RA group
